Loading…

Electrospun fibers for vaginal anti-HIV drug delivery

•Electrospun fibers can deliver a wide range of agents useful for topical HIV prevention.•Electrospun fiber meshes or fabrics for combination drug delivery can incorporate multiple agents via composites.•Polymeric fibers facilitate controlled drug release over relevant time frames.•Polymeric fibers...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral research 2013-12, Vol.100, p.S9-S16
Main Authors: Blakney, Anna K., Ball, Cameron, Krogstad, Emily A., Woodrow, Kim A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c371t-a76b65cdbdf488cf514f16178ed3ba21e1611c9f63b55e29aa5be34b8f1cd28f3
cites cdi_FETCH-LOGICAL-c371t-a76b65cdbdf488cf514f16178ed3ba21e1611c9f63b55e29aa5be34b8f1cd28f3
container_end_page S16
container_issue
container_start_page S9
container_title Antiviral research
container_volume 100
creator Blakney, Anna K.
Ball, Cameron
Krogstad, Emily A.
Woodrow, Kim A.
description •Electrospun fibers can deliver a wide range of agents useful for topical HIV prevention.•Electrospun fiber meshes or fabrics for combination drug delivery can incorporate multiple agents via composites.•Polymeric fibers facilitate controlled drug release over relevant time frames.•Polymeric fibers can be applied to both pericoital and sustained (coitally-independent) use. Diversity of microbicide delivery systems is essential for future success in the prevention and treatment of HIV in order to account for the varied populations of women all over the world that may benefit from use of these products. Recently, a novel dosage form for intravaginal drug delivery has been developed using drug-eluting fibers fabricated by electrospinning. There is a strong rationale to support the idea that drug-eluting fibers can be designed to realize multiple design constraints in a single product for topical HIV prevention: fibers are able to deliver a wide range of agents, incorporate multiple agents via composites, and facilitate controlled release over relevant time frames for pericoital and sustained (coitally-independent) use. It is also technologically feasible to scale-up production of fiber-based microbicides. Electrospun fibers may allow for prioritization of physical attributes that affect user perceptions without compromising biological efficacy. Challenges with using fibers as a microbicide include issues related to vehicle deployment, spreading and retention in the vaginal vault. In addition, studies will need to address the interaction of the fibers with the mucosal environment, including unknown safety and toxicity. Sustained release fiber microbicides capable of delivering multiple antiretroviral drugs while simultaneously exhibiting tunable degradation or dissolution of the fibers is also a challenge. However, electrospun fibers are a promising new platform for vaginal delivery of anti-HIV agents and future research will inform their place in the field. This article is based on a presentation at the “Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies”, held in Arlington, Virginia on February 20–21, 2013. It forms part of a special supplement to Antiviral Research.
doi_str_mv 10.1016/j.antiviral.2013.09.022
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1465864105</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354213002829</els_id><sourcerecordid>1465864105</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-a76b65cdbdf488cf514f16178ed3ba21e1611c9f63b55e29aa5be34b8f1cd28f3</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EglL4BciSTYLHiR1nWVU8KlViA2wtxx5XrtKk2E0l_h5XLWxZjUY6d67mEHIPtAAK4nFd6H7n9z7ormAUyoI2BWXsjExA1ixvaCPOySSRIi95xa7IdYxrSqmoG3lJrlgFUtYUJoQ_dWh2YYjbsc-cbzHEzA0h2-uV73WXHWry18VnZsO4yix2fo_h-4ZcON1FvD3NKfl4fnqfv-bLt5fFfLbMTVnDLte1aAU3trWuktI4DpUDAbVEW7aaAaYFTONE2XKOrNGat1hWrXRgLJOunJKH491tGL5GjDu18dFg1-kehzEqqASXogLKE1ofUZOeiQGd2ga_0eFbAVUHZ2qt_pypgzNFG5WcpeTdqWRsN2j_cr-SEjA7Aphe3XsMKhqPvUHrQ5Kn7OD_LfkBB-OBnQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1465864105</pqid></control><display><type>article</type><title>Electrospun fibers for vaginal anti-HIV drug delivery</title><source>ScienceDirect Journals</source><creator>Blakney, Anna K. ; Ball, Cameron ; Krogstad, Emily A. ; Woodrow, Kim A.</creator><creatorcontrib>Blakney, Anna K. ; Ball, Cameron ; Krogstad, Emily A. ; Woodrow, Kim A.</creatorcontrib><description>•Electrospun fibers can deliver a wide range of agents useful for topical HIV prevention.•Electrospun fiber meshes or fabrics for combination drug delivery can incorporate multiple agents via composites.•Polymeric fibers facilitate controlled drug release over relevant time frames.•Polymeric fibers can be applied to both pericoital and sustained (coitally-independent) use. Diversity of microbicide delivery systems is essential for future success in the prevention and treatment of HIV in order to account for the varied populations of women all over the world that may benefit from use of these products. Recently, a novel dosage form for intravaginal drug delivery has been developed using drug-eluting fibers fabricated by electrospinning. There is a strong rationale to support the idea that drug-eluting fibers can be designed to realize multiple design constraints in a single product for topical HIV prevention: fibers are able to deliver a wide range of agents, incorporate multiple agents via composites, and facilitate controlled release over relevant time frames for pericoital and sustained (coitally-independent) use. It is also technologically feasible to scale-up production of fiber-based microbicides. Electrospun fibers may allow for prioritization of physical attributes that affect user perceptions without compromising biological efficacy. Challenges with using fibers as a microbicide include issues related to vehicle deployment, spreading and retention in the vaginal vault. In addition, studies will need to address the interaction of the fibers with the mucosal environment, including unknown safety and toxicity. Sustained release fiber microbicides capable of delivering multiple antiretroviral drugs while simultaneously exhibiting tunable degradation or dissolution of the fibers is also a challenge. However, electrospun fibers are a promising new platform for vaginal delivery of anti-HIV agents and future research will inform their place in the field. This article is based on a presentation at the “Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies”, held in Arlington, Virginia on February 20–21, 2013. It forms part of a special supplement to Antiviral Research.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2013.09.022</identifier><identifier>PMID: 24188701</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Intravaginal ; Anti-HIV Agents - administration &amp; dosage ; Antiretroviral ; Drug Delivery Systems - instrumentation ; Drug Delivery Systems - methods ; Electrospun fibers ; Female ; HIV Infections - drug therapy ; HIV Infections - prevention &amp; control ; HIV Infections - virology ; HIV-1 - drug effects ; HIV-1 - physiology ; Human immunodeficiency virus ; Humans ; Microbicide ; Vaginal delivery</subject><ispartof>Antiviral research, 2013-12, Vol.100, p.S9-S16</ispartof><rights>2013 Elsevier B.V.</rights><rights>Copyright © 2013 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-a76b65cdbdf488cf514f16178ed3ba21e1611c9f63b55e29aa5be34b8f1cd28f3</citedby><cites>FETCH-LOGICAL-c371t-a76b65cdbdf488cf514f16178ed3ba21e1611c9f63b55e29aa5be34b8f1cd28f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24188701$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Blakney, Anna K.</creatorcontrib><creatorcontrib>Ball, Cameron</creatorcontrib><creatorcontrib>Krogstad, Emily A.</creatorcontrib><creatorcontrib>Woodrow, Kim A.</creatorcontrib><title>Electrospun fibers for vaginal anti-HIV drug delivery</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>•Electrospun fibers can deliver a wide range of agents useful for topical HIV prevention.•Electrospun fiber meshes or fabrics for combination drug delivery can incorporate multiple agents via composites.•Polymeric fibers facilitate controlled drug release over relevant time frames.•Polymeric fibers can be applied to both pericoital and sustained (coitally-independent) use. Diversity of microbicide delivery systems is essential for future success in the prevention and treatment of HIV in order to account for the varied populations of women all over the world that may benefit from use of these products. Recently, a novel dosage form for intravaginal drug delivery has been developed using drug-eluting fibers fabricated by electrospinning. There is a strong rationale to support the idea that drug-eluting fibers can be designed to realize multiple design constraints in a single product for topical HIV prevention: fibers are able to deliver a wide range of agents, incorporate multiple agents via composites, and facilitate controlled release over relevant time frames for pericoital and sustained (coitally-independent) use. It is also technologically feasible to scale-up production of fiber-based microbicides. Electrospun fibers may allow for prioritization of physical attributes that affect user perceptions without compromising biological efficacy. Challenges with using fibers as a microbicide include issues related to vehicle deployment, spreading and retention in the vaginal vault. In addition, studies will need to address the interaction of the fibers with the mucosal environment, including unknown safety and toxicity. Sustained release fiber microbicides capable of delivering multiple antiretroviral drugs while simultaneously exhibiting tunable degradation or dissolution of the fibers is also a challenge. However, electrospun fibers are a promising new platform for vaginal delivery of anti-HIV agents and future research will inform their place in the field. This article is based on a presentation at the “Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies”, held in Arlington, Virginia on February 20–21, 2013. It forms part of a special supplement to Antiviral Research.</description><subject>Administration, Intravaginal</subject><subject>Anti-HIV Agents - administration &amp; dosage</subject><subject>Antiretroviral</subject><subject>Drug Delivery Systems - instrumentation</subject><subject>Drug Delivery Systems - methods</subject><subject>Electrospun fibers</subject><subject>Female</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - prevention &amp; control</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - physiology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Microbicide</subject><subject>Vaginal delivery</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkMtOwzAQRS0EglL4BciSTYLHiR1nWVU8KlViA2wtxx5XrtKk2E0l_h5XLWxZjUY6d67mEHIPtAAK4nFd6H7n9z7ormAUyoI2BWXsjExA1ixvaCPOySSRIi95xa7IdYxrSqmoG3lJrlgFUtYUJoQ_dWh2YYjbsc-cbzHEzA0h2-uV73WXHWry18VnZsO4yix2fo_h-4ZcON1FvD3NKfl4fnqfv-bLt5fFfLbMTVnDLte1aAU3trWuktI4DpUDAbVEW7aaAaYFTONE2XKOrNGat1hWrXRgLJOunJKH491tGL5GjDu18dFg1-kehzEqqASXogLKE1ofUZOeiQGd2ga_0eFbAVUHZ2qt_pypgzNFG5WcpeTdqWRsN2j_cr-SEjA7Aphe3XsMKhqPvUHrQ5Kn7OD_LfkBB-OBnQ</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Blakney, Anna K.</creator><creator>Ball, Cameron</creator><creator>Krogstad, Emily A.</creator><creator>Woodrow, Kim A.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20131201</creationdate><title>Electrospun fibers for vaginal anti-HIV drug delivery</title><author>Blakney, Anna K. ; Ball, Cameron ; Krogstad, Emily A. ; Woodrow, Kim A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-a76b65cdbdf488cf514f16178ed3ba21e1611c9f63b55e29aa5be34b8f1cd28f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Administration, Intravaginal</topic><topic>Anti-HIV Agents - administration &amp; dosage</topic><topic>Antiretroviral</topic><topic>Drug Delivery Systems - instrumentation</topic><topic>Drug Delivery Systems - methods</topic><topic>Electrospun fibers</topic><topic>Female</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - prevention &amp; control</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - physiology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Microbicide</topic><topic>Vaginal delivery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blakney, Anna K.</creatorcontrib><creatorcontrib>Ball, Cameron</creatorcontrib><creatorcontrib>Krogstad, Emily A.</creatorcontrib><creatorcontrib>Woodrow, Kim A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blakney, Anna K.</au><au>Ball, Cameron</au><au>Krogstad, Emily A.</au><au>Woodrow, Kim A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Electrospun fibers for vaginal anti-HIV drug delivery</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>100</volume><spage>S9</spage><epage>S16</epage><pages>S9-S16</pages><issn>0166-3542</issn><eissn>1872-9096</eissn><abstract>•Electrospun fibers can deliver a wide range of agents useful for topical HIV prevention.•Electrospun fiber meshes or fabrics for combination drug delivery can incorporate multiple agents via composites.•Polymeric fibers facilitate controlled drug release over relevant time frames.•Polymeric fibers can be applied to both pericoital and sustained (coitally-independent) use. Diversity of microbicide delivery systems is essential for future success in the prevention and treatment of HIV in order to account for the varied populations of women all over the world that may benefit from use of these products. Recently, a novel dosage form for intravaginal drug delivery has been developed using drug-eluting fibers fabricated by electrospinning. There is a strong rationale to support the idea that drug-eluting fibers can be designed to realize multiple design constraints in a single product for topical HIV prevention: fibers are able to deliver a wide range of agents, incorporate multiple agents via composites, and facilitate controlled release over relevant time frames for pericoital and sustained (coitally-independent) use. It is also technologically feasible to scale-up production of fiber-based microbicides. Electrospun fibers may allow for prioritization of physical attributes that affect user perceptions without compromising biological efficacy. Challenges with using fibers as a microbicide include issues related to vehicle deployment, spreading and retention in the vaginal vault. In addition, studies will need to address the interaction of the fibers with the mucosal environment, including unknown safety and toxicity. Sustained release fiber microbicides capable of delivering multiple antiretroviral drugs while simultaneously exhibiting tunable degradation or dissolution of the fibers is also a challenge. However, electrospun fibers are a promising new platform for vaginal delivery of anti-HIV agents and future research will inform their place in the field. This article is based on a presentation at the “Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies”, held in Arlington, Virginia on February 20–21, 2013. It forms part of a special supplement to Antiviral Research.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>24188701</pmid><doi>10.1016/j.antiviral.2013.09.022</doi></addata></record>
fulltext fulltext
identifier ISSN: 0166-3542
ispartof Antiviral research, 2013-12, Vol.100, p.S9-S16
issn 0166-3542
1872-9096
language eng
recordid cdi_proquest_miscellaneous_1465864105
source ScienceDirect Journals
subjects Administration, Intravaginal
Anti-HIV Agents - administration & dosage
Antiretroviral
Drug Delivery Systems - instrumentation
Drug Delivery Systems - methods
Electrospun fibers
Female
HIV Infections - drug therapy
HIV Infections - prevention & control
HIV Infections - virology
HIV-1 - drug effects
HIV-1 - physiology
Human immunodeficiency virus
Humans
Microbicide
Vaginal delivery
title Electrospun fibers for vaginal anti-HIV drug delivery
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A03%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Electrospun%20fibers%20for%20vaginal%20anti-HIV%20drug%20delivery&rft.jtitle=Antiviral%20research&rft.au=Blakney,%20Anna%20K.&rft.date=2013-12-01&rft.volume=100&rft.spage=S9&rft.epage=S16&rft.pages=S9-S16&rft.issn=0166-3542&rft.eissn=1872-9096&rft_id=info:doi/10.1016/j.antiviral.2013.09.022&rft_dat=%3Cproquest_cross%3E1465864105%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c371t-a76b65cdbdf488cf514f16178ed3ba21e1611c9f63b55e29aa5be34b8f1cd28f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1465864105&rft_id=info:pmid/24188701&rfr_iscdi=true